期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 18, 期 5, 页码 473-486出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2018.1453361
关键词
Durvalumab; immunotherapy; ipilimumab; nivolumab; pembrolizumab; rovalpituzumab tesirine; SCLC; second-line; targeted therapy; tremelimumab
类别
Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC.Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC.Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据